Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Other Working Capital Changes (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Other Working Capital Changes readings, the most recent being -$126000.0 for Q4 2024.

  • On a quarterly basis, Other Working Capital Changes fell 72.6% to -$126000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$397000.0, a 57.54% decrease, with the full-year FY2025 number at -$565000.0, down 42.32% from a year prior.
  • Other Working Capital Changes hit -$126000.0 in Q4 2024 for Unicycive Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.4 million in Q3 2024 to a low of -$1.3 million in Q1 2024.
  • Median Other Working Capital Changes over the past 3 years was -$99500.0 (2023), compared with a mean of -$59250.0.
  • The widest YoY moves for Other Working Capital Changes: up 2097.22% in 2024, down 297.63% in 2024.
  • Unicycive Therapeutics' Other Working Capital Changes stood at $335000.0 in 2022, then crashed by 121.79% to -$73000.0 in 2023, then crashed by 72.6% to -$126000.0 in 2024.
  • The last three reported values for Other Working Capital Changes were -$126000.0 (Q4 2024), $1.4 million (Q3 2024), and -$365000.0 (Q2 2024) per Business Quant data.